Supernus Pharmaceuticals (SUPN) Competitors $42.00 -0.99 (-2.30%) Closing price 04:00 PM EasternExtended Trading$42.00 0.00 (0.00%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SUPN vs. CORT, JAZZ, PRGO, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJShould you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Supernus Pharmaceuticals vs. Its Competitors Corcept Therapeutics Jazz Pharmaceuticals Perrigo Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Supernus Pharmaceuticals (NASDAQ:SUPN) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings. Which has higher valuation & earnings, SUPN or CORT? Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSupernus Pharmaceuticals$661.82M3.56$73.86M$1.1536.52Corcept Therapeutics$675.04M10.96$141.21M$1.1362.12 Is SUPN or CORT more profitable? Corcept Therapeutics has a net margin of 18.51% compared to Supernus Pharmaceuticals' net margin of 9.70%. Corcept Therapeutics' return on equity of 20.10% beat Supernus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Supernus Pharmaceuticals9.70% 14.22% 10.82% Corcept Therapeutics 18.51%20.10%16.20% Do insiders and institutionals have more ownership in SUPN or CORT? 93.6% of Corcept Therapeutics shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, SUPN or CORT? Supernus Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Does the media refer more to SUPN or CORT? In the previous week, Corcept Therapeutics had 14 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 24 mentions for Corcept Therapeutics and 10 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 1.14 beat Supernus Pharmaceuticals' score of 0.40 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Corcept Therapeutics 19 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend SUPN or CORT? Supernus Pharmaceuticals currently has a consensus price target of $41.00, suggesting a potential downside of 2.38%. Corcept Therapeutics has a consensus price target of $134.50, suggesting a potential upside of 91.62%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supernus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCorcept Therapeutics beats Supernus Pharmaceuticals on 14 of the 16 factors compared between the two stocks. Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SUPN vs. The Competition Export to ExcelMetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.41B$4.17B$5.73B$9.80BDividend YieldN/A1.25%4.54%4.08%P/E Ratio36.5211.0430.7425.12Price / Sales3.5612.89441.58109.31Price / Cash10.317.0537.3459.16Price / Book2.214.848.886.24Net Income$73.86M-$109.62M$3.26B$265.56M7 Day Performance1.84%5.08%1.73%0.90%1 Month Performance29.87%23.52%3.54%1.88%1 Year Performance22.77%33.58%28.63%20.09% Supernus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SUPNSupernus Pharmaceuticals2.1381 of 5 stars$42.00-2.3%$41.00-2.4%+24.4%$2.41B$661.82M36.52580Insider TradeCORTCorcept Therapeutics4.7205 of 5 stars$71.97-0.5%$134.50+86.9%+111.2%$7.62B$675.04M63.69300Positive NewsJAZZJazz Pharmaceuticals4.5073 of 5 stars$110.75-0.5%$181.43+63.8%+6.0%$6.75B$4.07B-16.462,800Positive NewsPRGOPerrigo4.9588 of 5 stars$22.04-2.3%$33.00+49.8%-16.7%$3.10B$4.37B-37.998,379Positive NewsAnalyst UpgradeInsider TradePCRXPacira BioSciences3.4743 of 5 stars$25.19+0.0%$25.75+2.2%+92.3%$1.13B$700.97M-9.06720NKTRNektar Therapeutics4.345 of 5 stars$22.47-2.6%$88.33+293.1%+46.3%$286.11M$98.43M-2.55220Positive NewsOMEROmeros4.1459 of 5 stars$4.14+2.0%$18.00+334.8%+3.4%$250.75MN/A-1.56210Earnings ReportASMBAssembly Biosciences4.0593 of 5 stars$23.60-1.5%$33.00+39.8%+80.1%$183.90M$28.52M-4.23100Analyst ForecastHigh Trading VolumeCPIXCumberland Pharmaceuticals0.5313 of 5 stars$2.84-12.1%N/A+119.3%$48.32M$37.87M-12.9180Analyst UpgradeGap DownHigh Trading VolumeLLYEli Lilly and Company4.9993 of 5 stars$635.46+1.6%$977.65+53.8%-24.2%$592.15B$45.04B41.5347,000Trending NewsAnalyst DowngradeHigh Trading VolumeJNJJohnson & Johnson4.8442 of 5 stars$173.98+0.4%$174.50+0.3%+10.6%$417.44B$88.82B18.61138,100Positive News Related Companies and Tools Related Companies CORT Alternatives JAZZ Alternatives PRGO Alternatives PCRX Alternatives NKTR Alternatives OMER Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SUPN) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access